Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $29.00 price target on Trevi Therapeutics (NASDAQ: TRVI).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Stifel Reiterates Buy Rating on Trevi Therapeutics (TRVI)March 19, 2025 7:13 AM H.C. Wainwright Reiterates Buy Rating on Trevi Therapeutics (TRVI)March 19, 2025 6:43 AM Form S-8 Trevi Therapeutics, Inc. March 18, 2025 4:17 PM Form 10-K Trevi Therapeutics, Inc. For: Dec 31March 18, 2025 4:14 PM Form 8-K Trevi Therapeutics, Inc. For: Mar 18March 18, 2025 4:11 PM Trevi Therapeutics (TRVI) Tops Q4 EPS by 1cMarch 18, 2025 4:05 PM Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business UpdatesMarch 18, 2025 4:05 PM